H. Odhar

In silico Identification of FDA Approved Drug Candidates Targeting the RNA-binding Region of Andes Hantavirus Nucleocapsid Protein

Both Lifitegrast and Telmisartan seem to be prioritized computational candidates against RNA binding area of the Andes virus NP target.